港股IPO | 翰思艾泰:富德与国泰君安做基石,拥有全球首个且唯一双链路抗癌药产品,正在招股中

Ofweek光电信息网
Dec 17

作者丨Tom设计丨Tian发行情况资料来源:招股说明书财务情况由于目前公司处于临床研发阶段,目前没有获批商业化产品,因此无产品营业收入,公司其他收入方面主要来源于政府补助、结构性存款及理财产品利息收入。但知道注意的是,公司与中山康方共同开发的HX008,通过2017年至2019年期间订立的一系列股权转让协议,向乐普转让了HX008,以换取一次性现金款项人民币3.5亿元及占HX008年度销售收入净额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10